Petros Pharmaceuticals Receives Response From FDA Following Recent Demonstration Of Technology Component In Pursuit Of OTC Status For STENDRA
Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received